Lee Davy-Martin, partner and advisor to ambitious media, property & tech companies
Lee works closely with his clients, building long-term relationships and facilitating the provision of strategic and commercial advice. It is for this reason that Lee works particularly well with new business ventures and businesses which intend to restructure.
Lee has a diverse technical knowledge base acquired through acting for HNW and UHNW clients and has worked across most sectors.
Lee has particular experience of supporting businesses in the media & entertainment, technology and property sectors, especially those looking to achieve rapid growth.
Our dinners for tech business CEOs and founders
Lee hosts our programme of discussion dinners for technology entrepreneurs, which brings together CEOs of envirotech, fintech and meditech businesses so they can discuss with their peers their biggest challenges and dilemmas. Click here for information and to register your interest.
Areas of accountancy and business expertise
As well as general compliance, Lee specialises in holistic tax planning, restructuring businesses, and advising on when and how to make use of government approved tax schemes such as R&D tax credits and EIS/SEIS, which are being effectively used by a range of technology and other businesses to increase growth and/or attract investors.
Lee joined Wilson Wright in March 2012 having qualified as a chartered accountant in 2006 with a boutique central London practice specialising in private client work. Lee quickly became a partner having moved through the ranks and, after this firm was acquired by the Crowe Clark Whitehill group in 2010, Lee became one of its executive directors.
Away from the office Lee is a keen sportsman, playing squash at a competitive level and enjoys spending time with his wife and young son.
Lee has been working very closely for a number of years with UK-based tech company Agalimmune Ltd. Lee was the key advisor to the board when negotiating and working through due diligence on its recent acquisition by BioLineRx, an international clinical-stage biopharmaceutical listed company focused on oncology and immunology.
This unique deal achieved a partial exit for the founders and provides sufficient finance for the ongoing trials required to ultimately commercialise the technology.
A full account of the transaction can be found by visiting: